FDAsafety guidance72% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Roche.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Alzheimer's Disease
- Sub-indication
- General
Related signal: Hoffmann-La Roche initiates trial for trontinemab in early symptomatic Alzheimer's disease